Age-Dependent Associations Between Androgenetic Alopecia and Prostate Cancer Risk

    David A. Muller, Graham G. Giles, Rodney Sinclair, John L. Hopper, Dallas R. English, Gianluca Severi
    Image of study
    TLDR Early balding at 40 increases prostate cancer risk.
    This study investigated the association between androgenetic alopecia (AA) and prostate cancer risk in men. The results showed that vertex AA at age 40 years was associated with earlier age at onset of prostate cancer and increased cumulative probability of prostate cancer up to age 76 years. The study also found that a single, age-invariant estimate of relative risk is insufficient to describe the age-dependent association between AA and risk of prostate cancer.
    Discuss this study in the Community →

    Research cited in this study

    9 / 9 results

    Related Community Posts Join

    6 / 1000+ results

      community AGA evaluation and first steps - BEGINNER MEGAPOST

      in Chat  77 upvotes 1 year ago
      The conversation discusses androgenic alopecia (AGA) and its treatments, focusing on finasteride, minoxidil, and ketoconazole shampoo. Finasteride is recommended as essential for preventing further hair loss.

      community Male pattern baldness is not cosmetic.

      in Chat  212 upvotes 1 week ago
      Male pattern baldness is linked to health risks and should be treated medically. Finasteride is effective and should be insurance-covered.

      community Hair Loss Drugs Ranked in Order of Efficacy

      in Research/Science  67 upvotes 2 years ago
      Dutasteride is likely the most effective treatment for male pattern baldness, followed by finasteride and minoxidil in various forms and dosages. Users discuss personal experiences, dosages, and potential side effects, with some considering combining treatments for better results.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  39 upvotes 2 years ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

    Similar Research

    5 / 1000+ results